Control of stability of cyclin D1 by quinone reductase 2 in CWR22Rv1 prostate cancer cells

Carcinogenesis

Volumn 33, Issue 3, 2012, Pages 670-677

  Hsieh, Tze Chen ^a   Yang, Ching Jen ^b   Lin, Chia Yi ^a   Lee, Yong Syu ^a   Wu, Joseph M ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CHYMOTRYPSIN; CYCLIN D1; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; PROTEASOME; PROTEIN KINASE B; QUINONE REDUCTASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); RESVERATROL; RETINOBLASTOMA PROTEIN; SERINE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ARTICLE; ATTENUATION; CANCER CELL; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; GENE SILENCING; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; RECEPTOR DOWN REGULATION;

EID: 84863247474     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs016     Document Type: Article

References (39)

1. Long,D.J. II et al. (2000) NRH:quinone oxidoreductase2 (NQO2). Chem. Biol. Interact., 129, 99-112.
2. Chen,S. et al. (2000) Structure-function studies of DT-diaphorase (NQO1) and NRH: quinone oxidoreductase (NQO2). Free Radic. Biol. Med., 29, 276-284.
3. Sollner,S. et al. (2009) Quinone reductase acts as a redox switch of the 20S yeast proteasome. EMBO Rep., 10, 65-70.
4. Gong,X. et al. (2007) NRH:quinone oxidoreductase 2 and NAD(P)H: quinone oxidoreductase 1 protect tumor suppressor p53 against 20s proteasomal degradation leading to stabilization and activation of p53. Cancer Res., 67, 5380-5388.
5. Patrick,B.A. et al. (2011) Disruption of NAD(P)H:quinone oxidoreductase 1 gene in mice leads to 20S proteasomal degradation of p63 resulting in thinning of epithelium and chemical-induced skin cancer. Oncogene, 30, 1098-1107.
6. Garate,M. et al. (2008) NAD(P)H quinone oxidoreductase 1 inhibits the proteasomal degradation of the tumour suppressor p33(ING1b). EMBO Rep., 9, 576-581.
7. Sollner,S. et al. (2009) New roles of flavoproteins in molecular cell biology: an unexpected role for quinone reductases as regulators of proteasomal degradation. FEBS J., 276, 4313-4324.
8. Diehl,J.A. et al. (1997) Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev., 11, 957-972.
9. Diehl,J.A. et al. (1998) Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev., 12, 3499-3511.
10. Alt,J.R. et al. (2000) Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev., 14, 3102-3114.
11. Lukas,J. et al. (1996) Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRbcontrolled G1 checkpoint. Mol. Cell. Biol., 16, 6917-6925.
12. Jang,M. et al. (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science, 275, 218-220.
13. Hsieh,T.C. et al. (1999) Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines. Exp. Cell Res., 249, 109-115.
14. Hsieh,T.C. et al. (2000) Grape-derived chemopreventive agent resveratrol decreases prostate-specific antigen (PSA) expression in LNCaP cells by an androgen receptor (AR)-independent mechanism. Anticancer Res., 20, 225-228.
15. Narayanan,B.A. et al. (2003) Differential expression of genes induced by resveratrol in LNCaP cells: P53-mediated molecular targets. Int. J. Cancer, 104, 204-212.
16. Jones,S.B. et al. (2005) Resveratrol-induced gene expression profiles in human prostate cancer cells. Cancer Epidemiol. Biomarkers Prev., 14, 596-604.
17. Narayanan,N.K. et al. (2004) Resveratrol-induced cell growth inhibition and apoptosis is associated with modulation of phosphoglycerate mutase B in human prostate cancer cells: two-dimensional sodium dodecyl sulfatepolyacrylamide gel electrophoresis and mass spectrometry evaluation. Cancer Detect. Prev., 28, 443-452.
18. Gao,S. et al. (2004)Modulation of androgen receptor-dependent transcription by resveratrol and genistein in prostate cancer cells. Prostate, 59, 214-225.
19. Lin,H.Y. et al. (2002) Resveratrol induced serine phosphorylation of p53 causes apoptosis in a mutant p53 prostate cancer cell line. J. Urol., 168, 748-755.
20. Ates,O. et al. (2007) Neuroprotection by resveratrol against traumatic brain injury in rats. Mol. Cell. Biochem., 294, 137-144.
21. Das,D.K. et al. (2006) Resveratrol in cardioprotection: a therapeutic promise of alternative medicine. Mol. Interv., 6, 36-47.
22. Tikoo,K. et al. (2008) Change in histone H3 phosphorylation, MAP kinase p38, SIR 2 and p53 expression by resveratrol in preventing streptozotocin induced type I diabetic nephropathy. Free Radic. Res., 42, 397-404.
23. Anekonda,T.S. (2006) Resveratrol-a boon for treating Alzheimer's disease? Brain Res. Rev., 52, 316-326.
24. Gatz,S.A. et al. (2008) Take a break-resveratrol in action on DNA. Carcinogenesis, 29, 321-332.
25. Csaki,C. et al. (2008) Regulation of inflammation signalling by resveratrol in human chondrocytes in vitro. Biochem. Pharmacol., 75, 677-687.
26. Wang,Z. et al. (2004) Identification and purification of resveratrol targeting proteins using immobilized resveratrol affinity chromatography. Biochem. Biophys. Res. Commun., 323, 743-749.
27. DiPietrantonio,A.M. et al. (2000) Specific processing of poly(ADP-ribose) polymerase, accompanied by activation of caspase-3 and elevation/reduction of ceramide/hydrogen peroxide levels, during induction of apoptosis in host HL-60 cells infected by the human granulocytic ehrlichiosis (HGE) agent. IUBMB Life, 49, 49-55.
28. Hsieh,T.C. et al. (2002) Effects of extracts of Coriolus versicolor (I'm-Yunity) on cell-cycle progression and expression of interleukins-1 beta,-6, and -8 in promyelocytic HL-60 leukemic cells and mitogenically stimulated and nonstimulated human lymphocytes. J. Altern. Complement. Med., 8, 591-602.
29. Hsieh,T.C. et al. (2006) Induction of cell cycle changes and modulation of apoptogenic/anti-apoptotic and extracellular signaling regulatory protein expression by water extracts of I'm-Yunity (PSP). BMC Complement. Altern. Med., 6, 30.
30. Hsieh,T.C. (2009) Uptake of resveratrol and role of resveratrol-targeting protein, quinone reductase 2, in normally cultured human prostate cells. Asian J. Androl., 11, 653-661.
31. Hsieh,T.C. (2009) Antiproliferative effects of resveratrol and the mediating role of resveratrol targeting protein NQO2 in androgen receptor-positive, hormone-non-responsive CWR22Rv1 cells. Anticancer Res., 29, 3011-3017.
32. DiPietrantonio,A.M. et al. (1998) Regulation of G1/S transition and induction of apoptosis in HL-60 leukemia cells by fenretinide (4HPR). Int. J. Cancer, 78, 53-61.
33. Darzynkiewicz,Z. et al. (2001) Flow cytometry in analysis of cell cycle and apoptosis. Semin. Hematol., 38, 179-193.
34. Ahmad,N. et al. (2001) Resveratrol causes WAF-1/p21-mediated G(1)-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells. Clin. Cancer Res., 7, 1466-1473.
35. Benitez,D.A. et al. (2007) Mechanisms involved in resveratrol-induced apoptosis and cell cycle arrest in prostate cancer-derived cell lines. J. Androl., 28, 282-293.
36. Aggarwal,B.B. et al. (2004) Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res., 24, 2783-2840.
37. Asher,G. et al. (2003) P53 hot-spot mutants are resistant to ubiquitinindependent degradation by increased binding to NAD(P)H:quinone oxidoreductase 1. Proc. Natl Acad. Sci. USA, 100, 15065-15070.
38. Devlin,H.L. et al. (2008) Impairment of the DNA repair and growth arrest pathways by p53R2 silencing enhances DNA damage-induced apoptosis in a p53-dependent manner in prostate cancer cells. Mol. Cancer Res., 6, 808-818.
39. Ahn,K.S. et al. (2007) Deficiency of NRH:quinone oxidoreductase 2 differentially regulates TNF signaling in keratinocytes: up-regulation of apoptosis correlates with down-regulation of cell survival kinases. Cancer Res., 67, 10004-10011.